• 1.

    MacDougall IC, et al.. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019; 380:447458.

  • 2.

    Besarab A, et al.. The effects of normal versus anemic hematocrit on hemodialysis patients with cardiac disease. N Eng J Med 1998; 339:584590.

  • 3.

    Singh AK, et al.. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:20852098.

  • 4.

    Pfeffer MA, et al.. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Eng J Med 2009; 361:201932.

  • 5.

    Feldman HI, et al.. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13:73444.

  • 6.

    Szczech LA, et al.. Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 2008; 74:791798.

  • 7.

    McCullough P, et al.. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol 2013; 37:54958.

  • 8.

    Solomon SD, et al.. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363:114655.

  • 9.

    Macdougall IC, et al.. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenouslv. BMJ 1989; 299:157158.

  • 10.

    Anker S, et al.. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:24362448.

Trials and Tribulations: NHT, CHOIR, TREAT, PIVOTAL

The balance between iron and ESA dose

Lynda Szczech
Search for other papers by Lynda Szczech in
Current site
Google Scholar
Restricted access